YOLFTbeta
Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna

PUR · WAR

1.40PLN+0.00 (+0.14%)

Price History

Full chart

Market Stats

Previous Close1.40
Open1.41
Day Range1.39 – 1.41
52-Week Range1.35 – 6.89
Volume232.48K
Market Cap35.88M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.68
Dividend Yield0.00%
Beta0.21
50-Day Avg2.85
200-Day Avg2.85

About

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.

Company Details

  • CEODr. Filip Jelen M.B.A., Ph.D.
  • Employees7
  • HeadquartersSzczytnicka 11, Wroclaw, Poland, 50-382, Poland
  • Websitehttps://purebiologics.com

Leadership

  • Dr. Filip Jelen M.B.A., Ph.D.Co-founder & President of the Management Board
  • Dr. Slawomir WojcikMember of Management Board
  • Mr. Przemyslaw DudekHead of Information Technology
  • Dr. Ewelina Swiderek Ph.D.Head of Project Management

Financials

Income Statement

Currency: PLN2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.29M981.84K9.53M16.75M572.00K254.00K662.00K95.00K00
Growth (%)--23.82%+870.83%+75.75%-96.59%-55.59%+160.63%-85.65%-100.00%-
Cost of Revenue179.61K103.55K2.84M3.96M273.00K4.28M6.07M2.67M46.00K159.00K
Gross Profit1.11M878.29K6.69M12.79M299.00K-4.03M-5.41M-2.57M-46.00K-159.00K
Gross Margin86.06%89.45%70.19%76.37%52.27%-1585.43%-816.77%-2709.47%--
Operating Expense1.53M1.26M7.32M17.16M11.86M6.46M19.22M29.14M12.34M6.17M
Operating Income-419.45K-386.25K-631.02K-4.37M-11.56M-10.48M-24.63M-31.72M-12.38M-6.33M
Operating Margin-32.54%-39.34%-6.62%-26.07%-2020.28%-4126.77%-3720.39%-33387.37%--
EBITDA-384.21K-247.58K-464.51K-1.64M-8.30M-8.62M-22.78M-26.08M-12.24M-6.17M
EBITDA Margin-29.81%-25.22%-4.87%-9.79%-1450.52%-3392.91%-3440.63%-27449.47%--
Net Income-432.93K-412.72K-689.34K-4.70M-12.11M-13.07M-26.37M-35.69M-19.43M-9.82M
Net Income Margin-33.59%-42.04%-7.23%-28.08%-2116.26%-5146.06%-3983.69%-37572.63%--
R&D-3.06M4.61M14.93M18.39M20.58M23.79M8.24M38.00K2.74M
R&D as % of Total Revenue-311.97%48.32%89.10%3214.34%8102.36%3593.20%8674.74%--
Interest Expense13.47K13.03K14.16K302.00K349.00K227.00K329.00K3.83M1.33M2.20M
Interest Expense % of Total Revenue1.05%1.33%0.15%1.80%61.01%89.37%49.70%4034.74%--

Balance Sheet

Currency: PLN2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets951.82K1.33M6.58M21.79M18.94M47.19M33.01M22.74M2.34M4.94M
Total Liabilities640.12K1.12M4.36M14.57M21.83M7.70M14.71M20.84M15.46M19.09M
Total Equity311.70K209.77K2.22M7.21M-2.89M39.49M18.30M1.89M-13.12M-14.15M
Cash219.52K267.05K195.94K13.92M8.96M6.18M2.26M3.61M313.00K10.00K
Total Debt-155.00K93.83K5.37M5.00M3.11M2.86M12.94M14.06M16.01M
Net Debt-219.52K-112.05K-102.10K-8.55M-3.95M-3.06M602.00K9.33M13.75M16.00M

Cash Flow

Currency: PLN2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-710.24K-2.85M-2.49M5.33M-1.35M-24.04M-17.39M-23.26M-10.83M-6.28M
Investing Cash Flow-441.50K-162.15K-162.15K-161.92K-561.00K-28.48M15.35M391.00K3.56M939.00K
Financing Cash Flow-2.90M2.58M8.55M-3.05M49.73M-1.88M24.22M3.98M5.04M
Capital Expenditure441.50K162.15K162.15K161.92K561.00K673.00K5.76M176.00K00
Free Cash Flow-1.15M-2.85M-2.65M5.17M-1.91M-24.71M-23.14M-23.44M-10.83M-6.28M
FCF to OCF162.16%100.00%106.52%96.96%141.46%102.80%133.12%100.76%100.00%100.00%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025
EPS Estimate------------------------
EPS Actual-0.18-0.63-0.48-0.71-0.58-0.95-0.95-1.57-0.88-0.97-1.13-0.18-1.68-1.50-1.70-1.89-1.37-1.84-1.41-1.99-0.89-0.14-1.69-0.20
Surprise------------------------
Timing------------------------

Key Statistics & Ratios

Market Cap35.88M
Enterprise Value365.34M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1015.69
Price / Book1.59
EPS-1.68
Book Value-1.34
Revenue (TTM)-10.52M
Gross Profit (TTM)-26.00K
EBITDA-6.52M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1111.15%
Return on Assets-211.74%
Shares Outstanding12.24M
Shares Float10.70M
Beta0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 11, 20251042:621